Patients with unfavourable-risk relapsed or primary refractory classic Hodgkin 's lymphoma who had undergone autologous stem-cell transplantation were randomly assigned , by fixed-block randomisation with a computer-generated random number sequence , to receive @ cycles of @ mg/kg brentuximab vedotin or placebo intravenously every @ weeks , starting @-@ days after transplantation .